R Berges1,2, T Ebert3,4, W Schafhauser5, W Schultze-Seemann6, M Braun7, J Herden7, P Weib8, M Garcia Schürmann9, M Reimann10, C Bornhof11, F Oberpenning12, P Baur13, J Zumbé14, E Gronau15, W Diederichs16, O A Brinkman17, M Goepel18, A Göll19, K Hoefner20, M Kriegmair21, S Laabs22, B Planz23, G Platz24, A Heidenreich25,4. 1. PZ Köln (Campus Longerich, Campus Universitätsklinikum), Köln, Deutschland. R.Berges@DVPZ.de. 2. Dachverband der Prostatazentren Deutschlands e.V., Claire-Waldoff-Straße 3, 10117, Berlin, Deutschland. R.Berges@DVPZ.de. 3. PZ Metropolregion Nürnberg, Nürnberg, Deutschland. 4. Dachverband der Prostatazentren Deutschlands e.V., Claire-Waldoff-Straße 3, 10117, Berlin, Deutschland. 5. PZ Hochfranken-Fichtelgebirge, Marktredwitz, Deutschland. 6. PZ Freiburg, Freiburg, Deutschland. 7. PZ Köln (Campus Longerich, Campus Universitätsklinikum), Köln, Deutschland. 8. Kompetenznetz Prostata Siegen, Siegen, Deutschland. 9. PZ Niederrhein, Wesel, Deutschland. 10. PZ Moers, Moers, Deutschland. 11. PZ Nürnberg-Mittelfranken, Nürnberg, Deutschland. 12. PZ Bocholt, Bocholt, Deutschland. 13. PZ Nymphenburg, München, Deutschland. 14. PZ Leverkusen, Leverkusen, Deutschland. 15. PZ Münsterland, Münster, Deutschland. 16. Berliner PZ, Berlin, Deutschland. 17. PZ Emsland, Lingen, Deutschland. 18. PZ West, Velbert, Deutschland. 19. PZ am Alfried Krupp-Krankenhaus, Essen, Deutschland. 20. PZ Rhein-Ruhr, Oberhausen, Deutschland. 21. PZ der UCM, Planegg, Deutschland. 22. PZ Elbe-Weser, Stade, Deutschland. 23. PZ Emscher-Lippe, Gladbeck, Deutschland. 24. PZ Mainspitze, Rüsselsheim, Deutschland. 25. Euro-Prostatazentrum Aachen, Aachen, Deutschland.
Abstract
BACKGROUND: In prostate centers of the Governing Body of German Prostate Centers (DVPZ, Dachverband der Prostatazentren Deutschlands e.V.) treatment data from 3 university clinics, 21 treatment clinics, 3 private clinics and 330 general practitioners incorporated under 22 certificates are collated, in order to document the quality and type of cross-sectoral and interdisciplinary treatment, in particular of prostate cancer (PCA) patients. METHODS: This analysis is based on the DVPZ UroCloud data sets from 20 July 2015. The UroCloud reflects the web-based chronological disease development and quality parameters. For the descriptive analysis of particular key figures, available complete data sets were selected. RESULTS: Of the centers 22 held a valid certificate and fulfilled all required case numbers and structural prerequisites at the primary certification or recertification. In three cases a reauditing led to requirements before certification. Since 2005 a total of 9650 PCA patients have been pseudonymized and followed up (41,247 follow-up forms, 4.3 forms per patient). In 2014 the median number of newly documented PCA patients was 61 per center (minimum 7 and maximum 295). Radical prostatectomy (RP) dominated with 4491 (56 %) cases followed by primary hormonal therapy (1210 cases, 15 %), irradiation (809, 10 %) and non-interventional therapy, such as active surveillance (AS) or watchful waiting (WW) in 760 cases (10 %). A prostate-specific antigen (PSA) reduction was documented in 50 % of the patients with a preoperative PSA value > 20, in 60 % of pT4 tumors and in 50 % of patients with a tumor Gleason score of 9-10. A positive incision margin (R+) was found in in 15 % of pT2 stages, 41 % of pT3 stages and 85 % of pT4 stages. A secondary intervention was documented in 6.5 % of RP. CONCLUSION: The DVPZ certificate reflects the complete spectrum of treatment of PCA patients. The strength of the certificate lies in the documentation of patient development and a simultaneous collation of quality parameters.
BACKGROUND: In prostate centers of the Governing Body of German Prostate Centers (DVPZ, Dachverband der Prostatazentren Deutschlands e.V.) treatment data from 3 university clinics, 21 treatment clinics, 3 private clinics and 330 general practitioners incorporated under 22 certificates are collated, in order to document the quality and type of cross-sectoral and interdisciplinary treatment, in particular of prostate cancer (PCA) patients. METHODS: This analysis is based on the DVPZ UroCloud data sets from 20 July 2015. The UroCloud reflects the web-based chronological disease development and quality parameters. For the descriptive analysis of particular key figures, available complete data sets were selected. RESULTS: Of the centers 22 held a valid certificate and fulfilled all required case numbers and structural prerequisites at the primary certification or recertification. In three cases a reauditing led to requirements before certification. Since 2005 a total of 9650 PCApatients have been pseudonymized and followed up (41,247 follow-up forms, 4.3 forms per patient). In 2014 the median number of newly documented PCApatients was 61 per center (minimum 7 and maximum 295). Radical prostatectomy (RP) dominated with 4491 (56 %) cases followed by primary hormonal therapy (1210 cases, 15 %), irradiation (809, 10 %) and non-interventional therapy, such as active surveillance (AS) or watchful waiting (WW) in 760 cases (10 %). A prostate-specific antigen (PSA) reduction was documented in 50 % of the patients with a preoperative PSA value > 20, in 60 % of pT4 tumors and in 50 % of patients with a tumor Gleason score of 9-10. A positive incision margin (R+) was found in in 15 % of pT2 stages, 41 % of pT3 stages and 85 % of pT4 stages. A secondary intervention was documented in 6.5 % of RP. CONCLUSION: The DVPZ certificate reflects the complete spectrum of treatment of PCApatients. The strength of the certificate lies in the documentation of patient development and a simultaneous collation of quality parameters.
Authors: Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså Journal: Lancet Date: 2008-12-16 Impact factor: 79.321
Authors: Michael J Barry; Gerald L Andriole; Daniel J Culkin; Steven H Fox; Karen M Jones; Maureen H Carlyle; Timothy J Wilt Journal: Clin Trials Date: 2013-08-29 Impact factor: 2.486
Authors: Malcolm D Mason; Wendy R Parulekar; Matthew R Sydes; Michael Brundage; Peter Kirkbride; Mary Gospodarowicz; Richard Cowan; Edmund C Kostashuk; John Anderson; Gregory Swanson; Mahesh K B Parmar; Charles Hayter; Gordana Jovic; Andrea Hiltz; John Hetherington; Jinka Sathya; James B P Barber; Michael McKenzie; Salah El-Sharkawi; Luis Souhami; P D John Hardman; Bingshu E Chen; Padraig Warde Journal: J Clin Oncol Date: 2015-02-17 Impact factor: 44.544